Antihistamine OTC Switch Petition Slated For NDAC Debate May 11
This article was originally published in The Tan Sheet
FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.
You may also be interested in...
Drug manufacturers, with the guidance of FDA, are the only qualified parties to gather the data necessary to establish that a drug can be safely used without a prescription, the Consumer Healthcare Products Association asserts.
Newer second-generation antihistamines are safer than older Rx drugs discontinued for safety reasons, a commentary in the May/June Journal of the American Pharmaceutical Association asserts.
FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.